HK firm exits Biosensors for US$312.3m
Singapore
SHANDONG Weigao will be selling its entire 21.7 per cent stake in Singapore medical devices firm Biosensors International Group for US$312.3 million, because of increasing competition in China and its intention to focus on its main businesses.
Shandong Weigao, via its wholly owned subsidiary, Wellford Capital, will sell its stake to Bermuda's CB Medical Holdings at S$1.05 per share, which represents a premium of around 11.7 per cent to Biosensors' closing price of S$0.94 on Thursday.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Companies & Markets
Carrier AirAsia discloses new listing plans under RM6.8 billion units merger
Intel slides after tepid forecast spurs fears about comeback
Microsoft beats estimates as AI drives revenue
Crypto firm sues SEC to fend off oversight of Ethereum
Snap beats first-quarter expectations, shares jump 25%
Google parent announces first-ever dividend; beats on sales, profit; shares soar